Human papillomavirus and other risk factors for cervical cancer

Biomedicine and Pharmacotherapy

Volumn 51, Issue 6-7, 1997, Pages 268-275

  Bosch, F X ^a   Munoz N ^b   De Sanjose S ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

Author keywords

Cervical cancer; Epidemiology; Human papillomavirus; Review

Indexed keywords

CANCER VACCINE; VIRUS VACCINE;

CANCER PREVENTION; CANCER SCREENING; FEMALE; FOLLOW UP; HUMAN; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR; UTERINE CERVIX CANCER; WART VIRUS;

EID: 0030797011     PISSN: 07533322     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0753-3322(97)83542-1     Document Type: Article

References (36)

1. 1 Parkin DM, Pisani P, Ferlay J. Estimates of the world-wide incidence of eighteen major cancers in 1985. Int J Cancer 1993;54:594-606
2. 2 Pisani P, Parkin DM, Ferlay J. Estimates of the world-wide mortality from eighteen major cancers in 1985. Implications for prevention and projection of future burden. Int J Cancer 1993;55:891-903
3. o 120, 1992:960-1
4. 4 Muñoz N, Bosch FX & Kaldor JM. Does human papillomavirus cause cervical cancer? The state of the epidemiological evidence. Br J Cancer 1988;57:1-5
5. 5 IARC. Monographs on the evaluation of carcinogenic risks to humans, vol 64: Human papillomaviruses. Lyon: International Agency for Research on Cancer, 1995:52-7
6. 6 Bosch FX, Manos MM, Muñoz N et al. Prevalence of human papillomavirus in cervical cancer: a world-wide perspective. J Natl Cancer I 1995;87:796-802
7. 7 Viladiu P, Bosch FX, Castellsagué X et al. HPV DNA and antibodies to HPV 16 E2, L2 and E7 peptides as predictors of survival in patients with squamous cell cervical cancer. J Clin Oncol 1997;15(2):610-19
8. 8 Burger RA, Monk BJ, Kurosaki T et al. Human papillomavirus type 18: Association with poor prognosis in early stage cervical cancer. J Natl Cancer I 1996;88:1361-8
9. 9 Riou G, Favre M, Jeannel D et al. Association between poor prognosis in early-stage invasive cervical carcinomas and non-detection of HPV DNA. Lancet 1990;335:1171-4
10. 10 Baay MFC, Duk JM, Buerger MPM et al. Follow-up of antibody responses to human papillomavirus type 16 E7 in patients treated for cervical carcinoma. J Med Virol 1995;45:342-7
11. 11 Czeglédy J, Iosif C, Hansson BG et al. Can a test for E6/E7 transcripts of human papillomavirus type 16 serve as a diagnostic tool for the detection of mecrometastasis in cervical cancer? Int J Cancer (Pred Oncol) 1995;6:211-5
12. 12 Moreno V, Muñoz N, Bosch FX et al. Risk factors for progression of Cervical Intraepithelial Neoplasm Grade III to Invasive Cervical Cancer. Cancer Epidem Biomarkers rev 1995;4:459-67
13. 13 Koutsky LA, Holmes KK, Critchlow CW et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. The New Engl J Med 1992;327:1272-8
14. 14 Remmink AJ, Walboomers JM, Helmerhorst TJM et al. The presence of persistent high-risk HPV genotypes in dysplastic cervical lesions is associated with progressive diasease: natural history up to 36 months. Int J Cancer 1995;61:306-11
15. 15 Ho GYF, Burk RD, Klein S et al. Perisitent genital human papillomavirus infection as a risk factor for persistent cervical dysplasia. J Natl Cancer I 1995;87:1365-71
16. 16 Muñoz N, Kato I, Bosch FX et al. Cervical cancer and herpes simplex virus type 2: case-controls studies in Spain and Colombia, with special reference to immunoglobulin-G sub-classes. Int J Cancer 1995a;60:438-42
17. 17 de Sanjosé S, Muñoz N, Bosch FX et al. Sexually transmitted agents and cervical neoplasia in Colombia and Spain. Int J Cancer 1994;56:1-6
18. 18 de Sanjose S, Palacio v, Tafur L et al. Prostitution, HIV, and cervical neoplasia: a survey in Spain and Colombia. Cancer Epidem Biomarkers rev 1993;2:531-5
19. 19 Melbye M, Palefsky J, Gonzales J et al. Immune status as a determinant of human papillomavirus detection and its association with anal epithelial abnormalities. Int J Cancer 1990;46:203-6
20. 20 Muñoz N, Bosch FX, de Sanjosé S et al. Risk factors for cervical intraepithelial neoplasia grade III / carcinoma in situ in Spain and Colombia. Cancer Epidem Biomarkers rev 1993;2:423-31
21. 21 Eluf-Neto J, Booth M, Muñoz N et al. Human papillomavirus and invasive cervical cancer in Brazil. Br J Cancer 1994;69:114-9
22. 22 Bosch FX, Muñoz N, de Sanjosé S et al. Risk factors for cervical cancer in Colombia and Spain. Int J Cancer 1992;52:750-8
23. 23 Kjaer SK, Van den Brule AJC, Bock JE et al. Human Papillomavirus - The most significant risk determinant of cervical intraepithelial neoplasia. Int J Cancer 1996;65: 601-6
24. o 119. Lyon: International Agency for Research on Cancer, 1992;25-52
25. o 119. Lyon: International Agency for Research on Cancer, 1992;271-281
26. o 2. France: Ares-Serono Publications 1997;23-33
27. 27 Bosch FX, Muñoz N, De Sanjosé S et al. Importance of human papillomavirus endemicity in the incidence of cervical cancer: an extension of the hypothesis on sexual behavior. Cancer Epidem Biom 1994b;3:375-9
28. 28 Bosch FX, Castellsagué X, Muñoz N et al. Male sexual behavior and human papillomavirus DNA: key risk factors for cervical cancer in Spain. J Natl Cancer I 1996:88: 1060-7
29. 29 Muñoz N, Castellsagué X, Bosch FX et al. Difficulty in elucidating the male role in cervical cancer in Colombia, a high-risk area for the disease. J Natl Cancer I 1996;88: 1068-75
30. 30 Cuzìck J, Szarewski A et al. Human papillomavirus testing in primaty cervical screening. Lancet 1995;345:1533-6
31. 31 Breitburd F, Kirnbauer R, Hubbert NL et al. Immunization with viruslike particles form cottontail rabbit papillomavirus (CRPV) can protect against experimental CRPV infection. J Virol 1995;69:3959-63
32. 32 Suzich JA, Ghim S-J, Palmer-Hill FJ et al. Systemic immunization with papillomavirus L1 protein completely prevents the development of viral mucosal papillomas. P Natl Acad Sci USA 1995;92:11553-7
33. 33 Borysiewicz LK, Fiander A, Nimako M et al. A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer. Lancet 1996;347:1523-7
34. 34 Frazer I, Dunn LA, Fernando GJP et al. Animal and human studies on immunotherapeutic HPV vaccines. Proceedings of IARC/Mérieux Joint Meeting on HPV Vaccines and their Potential Use in the Prevention and Treatment of Cervical Neoplasia, Annecy, France, 12-14 December 1994
35. 35 Kast WM, Brandt RM, Sidney J et al. Role of HLA-A motifs in identification of potential CTL epitopes in human papillomavirus type 16 E6 and E7 proteins. J Immunol 1994;152:3904-12
36. 36 Schiller JT & Roden RBS. Papillomavirus-like particles. Papillomavirus Rep 1995;6:121-8